Buruli ulcer, also called "mbasu", is the third mycobacteriosis affecting humans, after leprosy and tuberculosis, which it even exceeds in terms of prevalence in certain areas of DR Congo. The World Health Organisation ranks it among emerging diseases. The treatment of this wound is complex. The objective of this study is firstly to prepare a hydrophilic cream based on metronidazole, Furadantine and chloramine, secondly to develop an HPLC-UV method for the quality control of this cream and finally, to study the stability of this product during its use. The results obtained in this study show that the cream used has good pharmaco-technical properties including good spreadability, ease of sampling and no lumps. The developed HPLC-UV method makes it possible to simultaneously analyze the three active ingredients in a relatively short time. Then, the product has good stability during its time of use. This hydrophilic cream is an important advance in the treatment of this disease.